|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00002211 |
|
Date of registration:
|
02/11/1999 |
|
Primary sponsor: |
|
|
Public title:
|
Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients
|
|
Scientific title:
|
An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) Plus Nelfinavir (NFV), Didanosine (ddI), and Stavudine (d4T) in Triple and Quadruple Treatment Regimens in HIV-1 Infected Individuals |
|
Date of first enrolment:
|
February 2004 |
|
Target sample size:
|
160 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00002211 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Safety Study, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria
You may be eligible for this study if you:
- Are at least 18 years old.
- Are HIV-positive.
- Have a CD4 count of at least 50 cells/mm3.
- Have a viral load of at least 20,000 copies/ml.
Exclusion Criteria
You will not be eligible for this study if you:
- Have taken d4T.
- Have taken protease inhibitors, including NFV.
- Have taken nonnucleoside reverse transcriptase inhibitors.
- Have taken ddI for 1 month or more.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
HIV Infections
|
|
Intervention(s)
|
|
Drug: Delavirdine mesylate
|
|
Drug: Didanosine
|
|
Drug: Nelfinavir mesylate
|
|
Drug: Stavudine
|
|
Secondary ID(s)
|
|
0073
|
|
228E
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|